Europe

Perrigo to acquire Omega Pharma for $4.5 billion

Friday, November 7, 2014

Perrigo, a Dublin, Ireland-based global provider of healthcare products, will acquire Omega Pharma, an OTC healthcare company headquartered in Nazareth, Belgium, for $4.5 billion, including a $3.1 billion purchase price plus assumption of $1.4 billion in debt. The transaction will enhance Perrigo’s OTC product offering and expand its distribution through Omega’s strong established platform. 

[Read More]

EFPIA, Innovative Medicines Initiative form $348.2M Ebola+ program

Friday, November 7, 2014

European Federation of Pharmaceutical Industries and Associations (EFPIA), a representative of the pharmaceutical industry operating in Europe, its specialized group Vaccines Europe and the Innovative Medicines Initiative have launched a $348.2 million call for proposals for an Innovative Medicines Initiative (IMI) program aimed to address the current Ebola crisis. The Ebola+ program will bring together the pharma industry and researchers in a collaborative program aimed to cover the current outbreak, as well as future needs in the space of hemorrhagic fevers.

[Read More]

AstraZeneca, Manchester University form Advanced Drug Delivery Center

Thursday, November 6, 2014

The University of Manchester and AstraZeneca have entered into a strategic collaboration to develop cutting-edge technologies designed to enhance the way drugs work and deliver better health outcomes for patients. Together, they are launching the North West Center for Advanced Drug Delivery, which will be housed in Manchester Pharmacy School and will have links into a wide range of research groups throughout the university.

[Read More]

CluePoints wins ENTENTE Life Science Investment Forum Award

Thursday, October 30, 2014

CluePoints, a provider of Centralized Statistical Monitoring (CSM) solutions for clinical trials, has secured an ENTENTE Life Science Investment Forum Award. The award program, which is organized by the ENTENTE project and supported by the European Commission and EuropaBio, recognized CluePoints as one of Belgium’s most innovative high technology businesses for its Central Statistical Monitoring (CSM) solution, which employs unique statistical algorithms to determine the quality, accuracy and integrity of clinical trial data.

[Read More]

European Union to boost Ebola research with $30.9 million

Thursday, October 23, 2014

The European Commission (E.C.) has announced $30.9 million from the European Union (E.U.) budget for urgently needed Ebola research. The funding will go to five projects, ranging from a large-scale clinical trial of a potential vaccine, to testing existing and novel compounds to treat Ebola. The money from Horizon 2020, an E.U. research and innovation program, will be provided via a fast-track procedure in order to start work as soon as possible. The commission also is working with industry on the further development of vaccines, drugs and diagnostics for Ebola and other haemorrhagic diseases within the Innovative Medicines Initiative.

[Read More]

SBRI Healthcare launches $4M competition

Wednesday, October 22, 2014

Small Business Research Initiative (SBRI) Healthcare, an NHS England funded initiative to develop innovative products that address unmet health needs, has launched the latest SBRI Healthcare competition, which aims to accelerate development and NHS adoption of new technologies. In the second tranche of funding this year, a further $4 million is on offer to companies working in priority healthcare areas, including brain injury; child and adolescent mental health; diabetic foot ulcers; imaging; and outpatient services.

[Read More]

AstraZeneca, University of Cambridge strengthen partnership

Friday, October 17, 2014

AstraZeneca, together with its global biologics R&D arm MedImmune, has entered into four new collaborations with the University of Cambridge, building further on their existing partnership. The latest collaborations reinforce AZ’s commitment to creating a permeable research infrastructure in Cambridge following its decision to locate one of its three global R&D centers and its global headquarters in the city, which has been home to MedImmune’s biologics research laboratories for 25 years.

[Read More]

Treeway, LACDR collaborate on ALS therapy development

Thursday, October 16, 2014

Treeway, a Netherlands-based, amyotrophic lateral sclerosis (ALS) R&D strategy-focused company, and the Leiden Academic Center for Drug Research (LACDR) at the University of Leiden, the Netherlands, have formed a collaboration focused on the optimization of clinical trial designs and data analysis for ALS through the use of population disease progression models. Both parties aim to obtain a better understanding of the disease by developing ALS physiology-based disease models and test the effect of interventions in the different identified pathways.

[Read More]